NewAmsterdam Pharma Company N.V. Ordinary Shares

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company that develops therapies to improve care for patients with cardiometabolic disease. Its lead candidate, Obicetrapib, is an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor being studied in various clinical trials as a monotherapy and in combination with ezetimibe to lower LDL-C in cardiovascular diseases. Obicetrapib is also in a Phase 2a clinical trial for Alzheimer's disease. The company is headquartered in Naarden, the Netherlands.